Ginkgoselect® overview
Clinical studies


The pharmacokinetic profile of Ginkgoselect® Phytosome® has been defined in experimental animals and in human volunteers. Its bioavailability has been compared to GBE.

Increase in plasma levels of total ginkgolides (A and B) and bilobalide in healthy volunteers(1)

Fifteen healthy volunteers were randomly divided into two groups and administered respectively 160 mg of free formulation of GBE (corresponding to 9.6 mg of terpene lactone) and 160 mg of Ginkgoselect® Phytosome® (corresponding to the same amount of terpene lactone). The subjects switched formulations after a week of wash out. Blood samples were collected at 30, 60, 120, 180, 240, 300 and 400 min after ingestion. Terpene lactone detection was performed by means of liquid cromatography/atmospheric pressure chemical ionization mass spectrometry (LC/APCI-ITMS).
Ginkgolides A, B and bilobalide were absorbed to a higher extent (about three-fold) after administration of Ginkgoselect® Phytosome®. As an example, the here reported chart, reports plasma concentrations of ginkgolide A which, according to AUC, shows a 3.5 folds higher absorption of the Ginkgoselect® Phytosome®.


Improvement of DHBA urinary excretion in healthy volunteers(2)

Ginkgoselect® Phytosome® (120 mg/day as GBE) or GBE were administered for 5 days to 6 healthy volunteers in a cross-over study. Urine samples were collected and analyzed twice daily and metabolite 3,4-dihydrobenzoic acid (DHBA) was determined by HPLC. Volunteers were asked to refrain from consuming flavonoids-rich foods for the duration of the study.

Expand Bibliography